Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for ‘Long COVID’ Multi-Organ Risk Assessment
July 06 2022 - 6:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) today has launched
PhenoRisk PACS™ RuO, a research-use-only NMR test for
molecular phenomics research on ‘Long COVID’ patients’ blood
samples, using a multiplexed combination of biomarkers discovered
at the Australian National Phenome Center (ANPC) at Murdoch
University, under Director Jeremy Nicholson. The PhenoRisk
PACS™ RuO test is promising for research on early-stage risk
factors, on longitudinal recovery monitoring and on potential
secondary organ damage in cardiovascular disease, type II diabetes,
kidney dysfunction and inflammation. It consists of an Avance™ IVDr
NMR spectroscopy system that is testing several biological
mechanisms of action simultaneously in a 20-minute blood-test from
SARS-CoV-2 acute infection survivors who suffer long-term sequelae,
termed either Post-Acute COVID Syndrome (PACS), or commonly known
as ‘Long COVID’ syndrome.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220706005075/en/
ANPC Molecular Phenomics NMR Lab (Photo:
Business Wire)
Recent publications have demonstrated that NMR is playing a
pivotal role in measuring COVID-19 progression based on phenomic
molecular signatures, and it is also providing new insights into
various PACS mechanisms of action, as well as into Long COVID
clinical management and treatment options. The PhenoRisk
PACS™ RuO test characterizes metabolic and proteomic
biomarkers of SARS-CoV-2 pathobiology, even in asymptomatic acute
COVID cases, thereby enabling multi-organ risk assessment, recovery
and therapeutic research in multiple Long COVID dysfunctions.
This new NMR test has the potential to quantitatively
discriminate PACS patients from healthy or fully recovered
individuals by studying COVID-triggered pheno-conversion, defined
as transient or persistent systemic change of the molecular
signatures in human plasma samples after acute infection.
Subsequent pheno-reversion of metabolic signatures detected by
PhenoRisk PACS™ RuO may indicate PACS recovery.
In addition to metabolism analytes, PhenoRisk PACS™
RuO quantifies composite signals for groups of glycoproteins
and phospholipids, which can indicate inflammation and
cardiovascular disease risk, as well as a new NMR biomarker called
Supramolecular Phospholipid Composite (SPC). These markers show
excellent discrimination of COVID-19 from controls, while the
Glyc/SPC ratio has been proposed as a useful molecular marker for
Long COVID, which could significantly augment current clinical and
therapeutic research.
Dr. Oscar Millet, leader of the Precision Medicine and
Metabolism group at CIC bioGUNE in Bilbao, Spain, commented:
“PhenoRisk PACS™ RuO is an automated, easy to use and
standardized approach to investigate the complex metabolomic
signatures induced by SARS-CoV-2. It enables clinical research on
the screening and monitoring of long-term sequelae after acute
COVID-19, in patients with Long COVID syndrome, and even in
asymptomatic subjects – a breakthrough in understanding PACS.”
Dr. Iris Mangelschots, President of Bruker BioSpin’s Applied,
Industrial and Clinical Division, commented: “We are very excited
to provide this multi-organ PACS risk screen to the clinical and
pharmaceutical research community, after the preliminary validation
by our partners in the International COVID-19 Research Network. We
believe that PhenoRisk PACS™ RuO could make a
significant contribution in research to combat the effects of Long
COVID.”
PhenoRisk PACS1.0™ RuO expands Bruker’s offering for
clinical research based on the company’s Avance™ IVDr NMR
platform, which already provides lipoprotein profiles (B.I.LISA)
and quantification of small molecules in plasma and urine
(B.I.QuantPS2.0, B.I.QuantUR1.1).
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220706005075/en/
Investor Contact: Justin Ward Senior Director of Investor
Relations & Corporate Development T: +1 (978) 663-3660, ext.
1479 E: Investor.relations@bruker.com
Media Contact: Thorsten Thiel, PhD Vice President of
Group Marketing Bruker BioSpin T: +49 (721) 5161–6500 E:
pr@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024